Want to see GB:GENI full AI Analyst Report?
GENinCode UK Ltd. (GENI) Price & Analysis
GENI Stock Chart & Stats
- Day’s Range
- GBX 0.62 - GBX 0.70
- 52-Week Range
- GBX 0.56 - GBX 4.90
- Previous Close
- GBX 0.66
- Volume
- 512.05K
- Average Volume (3M)
- 2.31M
- Market Cap
- GBP 4.97M
- Enterprise Value
- GBP 4.24M
- Total Cash (Recent Filing)
- GBP 2.05M
- Total Debt (Recent Filing)
- GBP 98.00K
- Price to Earnings (P/E)
- ―
- Beta
- -0.46
- Next Earnings
- Jun 08, 2027
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross Margin
Accelerating revenue and improving gross margin indicate better commercial traction and unit economics. If maintained, this combination can expand the company’s ability to fund operations internally, support investment in its diagnostics platform, and improve operating leverage as scale increases.
Modest Absolute Debt
Small absolute debt reduces immediate interest and refinancing pressure compared with a heavily indebted business. This provides some financial flexibility while management works to improve profitability, although the benefit is constrained by ongoing losses and cash consumption.
Reported EPS Growth
Reported positive EPS growth provides evidence that per-share performance has improved over the measured period, which could support future recovery if accompanied by better operating results. Its durability will depend on whether gains persist alongside revenue growth and progress toward profitability.
Bears Say
Deep And Persistent Unprofitability
Large and persistent losses show that the current cost base remains far above the revenue scale generated by the business. Without substantial operating improvement, continued losses can consume capital, restrict strategic investment, and delay any credible path to sustainable earnings.
Ongoing Cash Burn
Recurring negative operating and free cash flow means the company has not demonstrated self-funded operations. Continued cash burn can force reliance on external financing, limit investment in growth, and increase vulnerability if the business takes longer than expected to reach breakeven.
Material Equity Erosion
Sharp equity erosion materially weakens the balance sheet and reduces the capital cushion available to absorb further losses. The resulting increase in debt-to-equity raises financial risk and can constrain funding choices even though total debt remains small in absolute terms.
GENinCode UK Ltd. News
GENI FAQ
What was GENinCode UK Ltd.’s price range in the past 12 months?
What is GENinCode UK Ltd.’s market cap?
When is GENinCode UK Ltd.’s upcoming earnings report date?
How were GENinCode UK Ltd.’s earnings last quarter?
Is GENinCode UK Ltd. overvalued?
Does GENinCode UK Ltd. pay dividends?
What is GENinCode UK Ltd.’s EPS estimate?
How many shares outstanding does GENinCode UK Ltd. have?
What happened to GENinCode UK Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of GENinCode UK Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
GENinCode UK Ltd.
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Matthew Heaton Walls
- Employees
- 44
- Website
- www.genincode.com
- Address
- One St. Peters Square, Manchester, GM, M2 3DE, GB
GENinCode UK Ltd. (GENI) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 6 | 13 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 1 | 0 | 11 |









